MX2018000084A - Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. - Google Patents
Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.Info
- Publication number
- MX2018000084A MX2018000084A MX2018000084A MX2018000084A MX2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A
- Authority
- MX
- Mexico
- Prior art keywords
- composition containing
- pharmaceutical composition
- valsartan
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 2
- 229960000672 rosuvastatin Drugs 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación se refiere a una composición farmacéutica que comprende una primera composición que comprende amlodipino o una sal farmacéuticamente aceptable del mismo y valsartán o una sal farmacéuticamente aceptable del mismo; y una segunda composición que comprende rosuvastatina o una sal farmacéuticamente aceptable de la misma. La composición farmacéutica tiene excelente estabilidad y una velocidad de disolución alta. Mediante una combinación sinérgica de fármacos que tienen diferentes mecanismos, la composición farmacéutica puede aliviar los efectos secundarios de formulaciones individuales convencionales y, por lo tanto, se puede usar en mayor medida en la prevención y el tratamiento de enfermedades cardiovasculares, hipertensión, arteriosclerosis, hiperlipidemia y una enfermedad compleja de los mismos. La composición farmacéutica también mejora el cumplimiento de la medicación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150097373 | 2015-07-08 | ||
| PCT/KR2016/007464 WO2017007287A1 (ko) | 2015-07-08 | 2016-07-08 | 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000084A true MX2018000084A (es) | 2018-03-22 |
| MX380070B MX380070B (es) | 2025-03-11 |
Family
ID=57685860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000084A MX380070B (es) | 2015-07-08 | 2016-07-08 | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3320903B1 (es) |
| KR (1) | KR101875112B1 (es) |
| ES (1) | ES2882672T3 (es) |
| HU (1) | HUE055181T2 (es) |
| MX (1) | MX380070B (es) |
| PL (1) | PL3320903T3 (es) |
| PT (1) | PT3320903T (es) |
| WO (1) | WO2017007287A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101920996B1 (ko) * | 2017-04-26 | 2018-11-22 | 알보젠코리아 주식회사 | HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제 |
| KR102108396B1 (ko) * | 2018-04-25 | 2020-05-07 | 제일약품주식회사 | 약학적 제제 |
| KR101992400B1 (ko) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | 약학적 제제 |
| WO2020175922A2 (ko) * | 2019-02-26 | 2020-09-03 | 주식회사 대웅제약 | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
| KR20220026641A (ko) * | 2020-08-25 | 2022-03-07 | 주식회사 대웅제약 | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
| BR112023003323A2 (pt) * | 2020-08-25 | 2023-03-21 | Daewoong Pharmaceutical Co Ltd | Composição farmacêutica em forma de dosagem única |
| CN112315926A (zh) * | 2020-11-23 | 2021-02-05 | 常州制药厂有限公司 | 一种缬沙坦口服固体制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| AU2008344891A1 (en) * | 2007-12-31 | 2009-07-09 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
| KR20090091083A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 방출성이 제어된 심혈관계질환 치료용 약제학적 제제 |
| CN101637609A (zh) * | 2009-09-06 | 2010-02-03 | 王丽燕 | 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| WO2011102702A2 (en) * | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| KR101302243B1 (ko) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
| KR101302306B1 (ko) * | 2011-01-26 | 2013-09-03 | 씨제이제일제당 (주) | 고지혈증 복합제 |
| KR101446603B1 (ko) * | 2011-11-22 | 2014-10-07 | 주식회사 인트로팜텍 | 텔미사르탄을 포함하는 단층정 복합 제제 |
| EP2977048A4 (en) * | 2013-03-12 | 2017-04-26 | LG Life Sciences Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
| CZ2013783A3 (cs) * | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| KR101910901B1 (ko) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| KR20150034120A (ko) * | 2014-10-15 | 2015-04-02 | 대봉엘에스 주식회사 | 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제 |
-
2016
- 2016-07-08 ES ES16821693T patent/ES2882672T3/es active Active
- 2016-07-08 KR KR1020160087102A patent/KR101875112B1/ko active Active
- 2016-07-08 MX MX2018000084A patent/MX380070B/es unknown
- 2016-07-08 PL PL16821693T patent/PL3320903T3/pl unknown
- 2016-07-08 EP EP16821693.5A patent/EP3320903B1/en active Active
- 2016-07-08 PT PT168216935T patent/PT3320903T/pt unknown
- 2016-07-08 WO PCT/KR2016/007464 patent/WO2017007287A1/ko not_active Ceased
- 2016-07-08 HU HUE16821693A patent/HUE055181T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101875112B1 (ko) | 2018-07-09 |
| EP3320903A4 (en) | 2019-03-20 |
| KR20170007695A (ko) | 2017-01-19 |
| PT3320903T (pt) | 2021-08-19 |
| EP3320903A1 (en) | 2018-05-16 |
| ES2882672T3 (es) | 2021-12-02 |
| HUE055181T2 (hu) | 2021-11-29 |
| PL3320903T3 (pl) | 2021-12-06 |
| EP3320903B1 (en) | 2021-05-19 |
| MX380070B (es) | 2025-03-11 |
| WO2017007287A1 (ko) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| JP2012193216A5 (es) | ||
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| EA201692388A1 (ru) | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| WO2011159100A3 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| MX2022004739A (es) | Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo. | |
| HK1214519A1 (zh) | 雙用途硫酸鹽口服藥物組合物片劑及其使用方法 | |
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| TN2019000063A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| EA201892842A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| MX2018015759A (es) | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. | |
| HK1218861A1 (zh) | 包含异烟肼颗粒和利福喷汀颗粒的呈可分散的片剂形式的抗结核病的稳定的药物组合物及其制备方法 | |
| WO2011161223A3 (en) | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts | |
| WO2020175922A3 (ko) | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 | |
| PH12020551547A1 (en) | Pharmaceutical preparation |